• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?

作者信息

Bergmann K C, Maurer M, Church M K, Zuberbier T

机构信息

Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

出版信息

J Investig Allergol Clin Immunol. 2020 Aug;30(4):285-287. doi: 10.18176/jiaci.0492.

DOI:10.18176/jiaci.0492
PMID:32723701
Abstract
摘要

相似文献

1
Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?单例患者对美泊利单抗和奥马珠单抗的过敏反应：是聚山梨酯的问题吗？
J Investig Allergol Clin Immunol. 2020 Aug;30(4):285-287. doi: 10.18176/jiaci.0492.
2
Mepolizumab (Nucala°) in asthma.美泊利珠单抗（Nucala°）用于治疗哮喘。
Prescrire Int. 2017 Feb;26(179):38-39.
3
Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.在长期治疗成功后使用奥马珠单抗后两名患者出现类过敏反应。
Allergy Asthma Proc. 2007 May-Jun;28(3):313-9. doi: 10.2500/aap.2007.28.3003.
4
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.美泊利珠单抗和奥马珠单抗治疗重度哮喘的比较疗效：间接治疗比较
Respir Med. 2017 Feb;123:140-148. doi: 10.1016/j.rmed.2016.12.009. Epub 2016 Dec 21.
5
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.美泊利珠单抗替代奥马珠单抗治疗未控制的严重嗜酸性粒细胞性哮喘的临床获益。
Allergy. 2019 Sep;74(9):1716-1726. doi: 10.1111/all.13850. Epub 2019 Jul 1.
6
Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.哮喘和过敏性疾病生物制剂的过敏和不良反应。
Expert Rev Clin Immunol. 2020 Mar;16(3):311-319. doi: 10.1080/1744666X.2020.1724089. Epub 2020 Feb 8.
7
Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system.哮喘的生物治疗相关不良反应：向葡萄牙药物警戒系统报告的分析。
Expert Opin Drug Saf. 2020 Jan;19(1):99-106. doi: 10.1080/14740338.2020.1686481. Epub 2019 Oct 31.
8
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab.美泊利珠单抗和奥马珠单抗有效治疗伴有嗜酸性胃肠炎的重度哮喘。
Ann Allergy Asthma Immunol. 2018 Dec;121(6):742-743. doi: 10.1016/j.anai.2018.07.030. Epub 2018 Jul 27.
9
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.美泊利珠单抗治疗既往使用奥马珠单抗治疗的重度嗜酸性粒细胞性哮喘患者的疗效
Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24.
10
Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.奥马珠单抗与变应原免疫疗法治疗1例哮喘合并吸入性糖皮质激素所致肾上腺抑制患者
Ann Allergy Asthma Immunol. 2016 Sep;117(3):335-7. doi: 10.1016/j.anai.2016.07.017.

引用本文的文献

1
A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.哮喘生物制剂严重过敏反应的风险：基于全球真实世界数据库的药物警戒研究。
Sci Rep. 2023 Oct 17;13(1):17607. doi: 10.1038/s41598-023-44973-z.
2
Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine.对奥马珠单抗的过敏反应：源自对 2019 年冠状病毒疫苗的反应的教训。
Intern Med. 2023 Apr 15;62(8):1219-1222. doi: 10.2169/internalmedicine.1169-22. Epub 2023 Feb 1.
3
Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates.
蛋白质治疗药物中用于蛋白质稳定化的替代辅料：克服聚山梨酯的局限性
Pharmaceutics. 2022 Nov 23;14(12):2575. doi: 10.3390/pharmaceutics14122575.
4
Anaphylaxis to Excipients in Current Clinical Practice: Evaluation and Management.当前临床实践中辅料的过敏反应：评估与管理。
Immunol Allergy Clin North Am. 2022 May;42(2):239-267. doi: 10.1016/j.iac.2021.12.008. Epub 2022 Mar 31.
5
Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy.10名确诊对聚乙二醇过敏的患者耐受杨森新冠疫苗。
J Allergy Clin Immunol Pract. 2022 Mar;10(3):859-862. doi: 10.1016/j.jaip.2021.12.025. Epub 2022 Jan 1.
6
Biologics for atopic diseases: Indication, side effect management, and new developments.用于特应性疾病的生物制剂：适应证、副作用管理及新进展。
Allergol Select. 2021 Jan 5;5:1-25. doi: 10.5414/ALX02197E. eCollection 2021.